ERBB2 and breast carcinoma: A study used SEER-Medicare data also reported that AC-TH was not associated with a higher rate of serious adverse events than TCH regimen14, indicating anthracycline-taxane based chemotherapy plus trastuzumab (AC-TH) is also a reasonable and safe regimen for high risk older HER2+ breast cancer patients.